Michael Barbella, Managing Editor03.04.23
A patient personalization partnership between two major orthopedic firms drove most site traffic to ODT this past week.
The collaboration between Medical 3D printing and planning solutions provider Materialise and Exactech aims to provide advanced treatment options for patients with severe shoulder defects. Exactech will include Materialise Glenius in its portfolio to enable surgeons to help patients with personalized implants in Europe and Australia. Orthopedic surgeons can use Materialise’s personalized implants to treat patients with substantial glenoid bone loss, for whom standard and augmented shoulder implants wouldn’t lead to sustainable results.
Study results were of interest as well, particularly those from Premia Spine and Moximed. The former shared outcomes from the TOPS facet joint replacement system’s clinical trial, which concluded that lumbar facet arthroplasty with the TOPS device was statistically better than lumbar fusion in all patient-reported outcome measures, a low surgical complication rate, and the ability to maintain motion at the index level while limiting sagittal translation. Two-year IDE study results of Moximed's MISHA knee system, meanwhile, found MISHA to be superior to high tibial osteotomy (HTO) against a two-year composite endpoint, demonstrating pain relief, functional improvement, and positive safety profile in medial knee osteoarthritis patients.
Other site traffic drivers this past week included Theradaptive's $4 million grant from the U.S. government for OsteoAdapt clinical study funding, and Xtant Surgical's $17 million purchase of Surgalign's Coflex and Cofix product lines. Coflex is an interlaminar stabilization device used after an open decompression, offering a non-fusion treatment for lumbar spinal stenosis (LSS) patients. It’s the only FDA PMA-approved implant for LSS treatment and has been implanted in more than 200,000 patients in over 60 countries. Cofix is a supplemental fixation device, a minimally invasive system for use on all lumbar spine levels.
The collaboration between Medical 3D printing and planning solutions provider Materialise and Exactech aims to provide advanced treatment options for patients with severe shoulder defects. Exactech will include Materialise Glenius in its portfolio to enable surgeons to help patients with personalized implants in Europe and Australia. Orthopedic surgeons can use Materialise’s personalized implants to treat patients with substantial glenoid bone loss, for whom standard and augmented shoulder implants wouldn’t lead to sustainable results.
Study results were of interest as well, particularly those from Premia Spine and Moximed. The former shared outcomes from the TOPS facet joint replacement system’s clinical trial, which concluded that lumbar facet arthroplasty with the TOPS device was statistically better than lumbar fusion in all patient-reported outcome measures, a low surgical complication rate, and the ability to maintain motion at the index level while limiting sagittal translation. Two-year IDE study results of Moximed's MISHA knee system, meanwhile, found MISHA to be superior to high tibial osteotomy (HTO) against a two-year composite endpoint, demonstrating pain relief, functional improvement, and positive safety profile in medial knee osteoarthritis patients.
Other site traffic drivers this past week included Theradaptive's $4 million grant from the U.S. government for OsteoAdapt clinical study funding, and Xtant Surgical's $17 million purchase of Surgalign's Coflex and Cofix product lines. Coflex is an interlaminar stabilization device used after an open decompression, offering a non-fusion treatment for lumbar spinal stenosis (LSS) patients. It’s the only FDA PMA-approved implant for LSS treatment and has been implanted in more than 200,000 patients in over 60 countries. Cofix is a supplemental fixation device, a minimally invasive system for use on all lumbar spine levels.